| Ding Ngui, | |
|
18491 Colima Rd, Rowland Heights, CA 91748-2805 | |
| (626) 581-3133 | |
| Not Available |
| Full Name | Ding Ngui |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 18491 Colima Rd, Rowland Heights, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124472493 | NPI | - | NPPES |
| 46526 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P0018X | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist | 48194 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ding Ngui, 18491 Colima Rd, Rowland Heights, CA 91748-2805 Ph: (626) 581-3133 | Ding Ngui, 18491 Colima Rd, Rowland Heights, CA 91748-2805 Ph: (626) 581-3133 |
News Archive
Scientists of the Technical University of Munich and the Max Planck Institute of Psychiatry have identified four new risk genes that are altered in German patients with multiple sclerosis (MS).
Results of a Pfizer-commissioned study published this month in Annals of Internal Medicine reveal that smokers with a past or present diagnosis of major depressive disorder (MDD)* taking varenicline had a significantly higher likelihood of quitting smoking (after 12 weeks and at 52 weeks) than those who were given a placebo.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Ipsen announced today that the preliminary data from the ongoing phase IIb study in patients with acromegaly for its chimeric compound BIM 23A760 does not meet the expected inhibition of growth hormone (GH) and IGF-1 levels after repeat dosing. Preliminary phase IIb data showed a strong dopaminergic activity but only weak evidence of somatostatinergic activity.
› Verified 4 days ago
Angela Zhi-jie Liu, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1724 Nogales St, Rowland Heights, CA 91748 Phone: 626-810-8211 | |
Gerald Chen, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 19169 Kim Ct, Rowland Heights, CA 91748 Phone: 626-315-5192 | |
Yuanzi Feng, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 18209 Madonna St, Rowland Heights, CA 91748 Phone: 626-416-8663 | |
Inseon Lim Chung, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1722 Desire Ave #103, C/o New Life Pharmacy, Rowland Heights, CA 91748 Phone: 626-839-3000 Fax: 626-521-5283 | |
Jiaxin Tan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 18397 Colima Rd, Rowland Heights, CA 91748 Phone: 626-581-8555 | |
Wendy Wu, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 18308 Colima Rd, Rowland Heights, CA 91748 Phone: 626-913-1033 Fax: 626-913-1053 |